CORONA Remedies Limited (NSE:CORONA)

India · Delayed Price · Currency is INR

2,098.20

-14.80 (-0.70%)

At close: Jul 27, 2026

Market Cap	128.33B
Revenue (ttm)	14.03B +20.1%
Net Income	1.85B +31.6%
EPS	30.27 +31.7%
Shares Out	61.16M
PE Ratio	69.32
Forward PE	51.33
Dividend	10.00 (0.47%)
Ex-Dividend Date	Jun 19, 2026

Volume	20,186
Open	2,126.80
Previous Close	2,113.00
Day's Range	2,086.60 - 2,140.00
52-Week Range	1,336.60 - 2,128.40
Beta	n/a
Analysts	Strong Buy
Price Target	1,929.00 (-8.06%)
Earnings Date	Jul 31, 2026

About CORONA Remedies

CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India. [Read more]

Industry Pharmaceutical Preparations

Founded 2004

Employees 5,153

Stock Exchange National Stock Exchange of India

Ticker Symbol CORONA

Full Company Profile

Financial Performance

In fiscal year 2026, CORONA Remedies's revenue was 14.03 billion, an increase of 17.28% compared to the previous year's 11.96 billion. Earnings were 1.85 billion, an increase of 23.88%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for CORONA stock is "Strong Buy." The 12-month stock price target is ₹1,929, which is a decrease of -8.06% from the latest price.

Price Target

₹1,929

(-8.06% downside)

Analyst Consensus: Strong Buy

Stock Forecasts